Evidence map›Paper›PMID 33790576›Full record

ArticleOncoTargets and therapy2021

Identification of Novel Alectinib-Resistant

Ping Yang, Ran Cao, Hua Bao, Xue Wu, Lingling Yang, Dongqin Zhu, Lu Zhang, Liming Peng, Yuefei Cai, Weijun Zhang and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ping Yang *Department of Radiation Oncology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, People's Republic of China.
Ran Cao *Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Hua BaoNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Xue WuNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Lingling YangNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Dongqin ZhuNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Lu ZhangDepartment of Medical Oncology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, People's Republic of China.
Liming PengDepartment of Respiratory Medicine, Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, People's Republic of China.
Yuefei CaiDepartment of Intervention, Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, People's Republic of China.
Weijun ZhangDepartments of Radiation Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Yang ShaoNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Tung Wah Hospital · CNGuangzhou Medical University · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug resistance caused by G1202R/G1202del mutation in anaplastic lymphoma kinase ( CASE PRESENTATION: A 50-year-old Chinese male non-smoker with lung adenocarcinoma progressed with spinal metastasis after receiving chest radiation together with Pemetrexed and Cisplatin as adjuvant chemotherapy. Targeted next generation sequencing (NGS) identified

conclusionOur case suggested the

Indexed as

Alectinibbinding energy calculationdrug resistancein silico predictionLorlatiniblung cancer

Identifiers

PMID33790576
PMCPMC8007639
OpenAlexW3152109309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.